Cancer, diabetes, and angiotensin blockade: A question of hypohydration

Journal of Clinical Oncology

Volumn 29, Issue 33, 2011, Pages 4465-4466

  Thornton, Simon N ^a,b  

^a UNIVERSITÉ DE LORRAINE   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RENIN;

AEROBIC METABOLISM; ANAEROBIC METABOLISM; BLOOD FLOW; BLOOD VOLUME; CARDIOVASCULAR AUTOREGULATION; DEHYDRATION; DIABETES MELLITUS; EXTRACELLULAR SPACE; HUMAN; HYPOVOLEMIA; HYPOXIA; LETTER; MITOCHONDRIAL RESPIRATION; NEOPLASM; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; NEOPLASMS;

EID: 81755171102     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.2069     Document Type: Letter

References (19)

1. Vigneri P, Frasca F, Sciacca L, et al.: Diabetes and cancer. Endocr Relat Cancer 16:1103-1123, 2009
2. Parekh N, Okada T, Lu-Yao GL: Obesity, insulin resistance, and cancer prognosis: Implications for practice for providing care among cancer survivors. J Am Diet Assoc 109:1346-1353, 2009
3. Chang CH, Lin JW, Wu LC, et al.: Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: A nationwide case-control study. J Clin Oncol 29:3001-3007, 2011
4. Portero-Otín M, Pamplona R, Boada J, et al.: Inhibition of renin angiotensin system decreases renal protein oxidative damage in diabetic rats. Biochem Biophys Res Commun 368:528-535, 2008
5. Okura T, Kojima M, Machida H, et al.: Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria. J Hum Hypertens [Epub ahead of print on March 17, 2011]
6. Haller H, Ito S, Izzo JL Jr, et al.: Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 364:907-917, 2011
7. Molteni A, Heffelfinger S, Moulder JE, et al.: Potential deployment of angiotensin I converting enzyme inhibitors and of angiotensin II type 1 and type 2 receptor blockers in cancer chemotherapy. Anticancer Agents Med Chem 6:451-460, 2006 (Pubitemid 44377779)
8. Heffelfinger SC: The renin angiotensin system in the regulation of angiogenesis. Curr Pharm Des 13:1215-1229, 2007
9. Ishiguro H, Ishiguro Y, Kubota Y, et al.: Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action. Prostate 67:924-932, 2007 (Pubitemid 46828926)
10. Thornton SN: Thirst and hydration: Physiology and consequences of dysfunction. Physiol Behav 100:15-21, 2010
11. Thornton SN: Angiotensin-induced metabolic dysfunction. J Hyperten 27:658-659, 2009
12. Thornton SN: Hypovolaemia-induced mild hypoxia produces sub-chronic metabolic dysfunction. Int J Obes (Lond) 33:605, 2009
13. Regazzetti C, Peraldi P, Grémeaux T, et al.: Hypoxia decreases insulin signaling pathways in adipocytes. Diabetes 58:95-103, 2009
14. Denko NC: Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8:705-713, 2008
15. Frezza C, Gottlieb E: Mitochondria in cancer: Not just innocent bystanders. Semin Cancer Biol 19:4-11, 2009
16. Semenza GL: HIF-1: Upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20:51-56, 2010
17. Klimova T, Chandel NS: Mitochondrial complex III regulates hypoxic activation of HIF. Cell Death Differ 15:660-666, 2008 (Pubitemid 351405069)
18. Thornton SN, Even PC, van Dijk G: Hydration increases cell metabolism. Int J Obes (Lond) 33:385, 2009
19. Altieri A, La Vecchia C, Negri E: Fluid intake and risk of bladder and other cancers. Eur J Clin Nutr 57:S59-S68, 2003 (Pubitemid 38159630)